Article
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Blood - 21 Jan 2016
Thompson Philip A, Tam Constantine S, O'Brien Susan M, Wierda William G, Stingo Francesco, Plunkett William, Smith Susan C, Kantarjian Hagop M, Freireich Emil J, Keating Michael J
Abstract excerpt
Accurate identification of patients likely to achieve long-progression-free survival (PFS) after chemoimmunotherapy is essential given the availability of less toxic alternatives, such as ibrutinib. Fludarabine, cyclophosphamide, and rituximab (FCR) achieved a high response rate, but continued relapses were seen in initial reports. We reviewed the original 300 patient phase 2 FCR study to identify long-term...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.